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Abstract
Introduction: Transfusion-related acute lung injury is emerging as a common cause of transfusion-
related adverse events. However, awareness about this entity in the medical fraternity is low and
it, consequently, remains a very under-reported and often an under-diagnosed complication of
transfusion therapy.
Case presentation: We report a case of a 46-year old woman who developed acute respiratory
and hemodynamic instability following a single unit blood transfusion in the postoperative period.
Investigation results were non-specific and a diagnosis of transfusion-related acute lung injury was
made after excluding other possible causes of acute lung injury. She responded to symptomatic
management with ventilatory and vasopressor support and recovered completely over the next 72
hours.
Conclusion: The diagnosis of transfusion-related acute lung injury relies on excluding other causes
of acute pulmonary edema following transfusion, such as sepsis, volume overload, and cardiogenic
pulmonary edema. All plasma containing blood products have been implicated in transfusion-
related acute lung injury, with the majority being linked to whole blood, packed red blood cells,
platelets, and fresh-frozen plasma. The pathogenesis of transfusion-related acute lung injury may be
explained by a "two-hit" hypothesis, involving priming of the inflammatory machinery and then
activation of this primed mechanism. Treatment is supportive, with prognosis being substantially
better than for most other causes of acute lung injury.
Introduction
Transfusion-related acute lung injury (TRALI) is a fre-
quently misdiagnosed, yet potentially fatal reaction fol-
lowing transfusion of blood products. There is much
confusion in the literature regarding this entity because
until recently, there was no uniform nomenclature, defi-
nition or diagnostic features described in relation to it.
We describe a case report of TRALI, not because it is infre-
quent, unique or has never been described before, but to
familiarize our colleagues with it. The intention of this
article is to compile available information to educate our-
selves to a potentially preventable life-threatening condi-
tion and the current guidelines for its management.
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Case presentation
A 46-year old woman of Indian origin complained of
breathlessness along with chest discomfort in the ICU,
where she was recuperating from a laparotomy for ovarian
malignancy. Her complaints had started within 20 to 25
minutes of completion of a transfusion of a single unit of
packed red blood cells (PRBC). Rapid clinical deteriora-
tion was noted with a falling oxygen saturation (<80%),
hypotension (systolic BP of <80 mmHg), tachycardia
(>140/minute), tachypnea (>30/minute), and mild fever
(100°F). An urgent chest X-ray was ordered and showed
extensive bilateral pulmonary infiltrates (Figure 1). Inva-
sive monitoring was initiated and a panel of investiga-
tions was ordered immediately (Table 1). Hemodynamic
parameters progressively worsened with onset of respira-
tory distress. In the setting of a deteriorating clinical con-
dition, the patient was supported with mechanical
ventilation using a positive end expiratory pressure
(PEEP) of 10 mmHg along with multi-agent hemody-
namic support (dopamine, dobutamine and noradrena-
line). Over a period of 72 hours, the patient responded to
symptomatic measures. Her hemodynamic parameters
improved and the vasopressor support could be with-
drawn after 48 hours. However, recovery from the pulmo-
nary insult was slower. X-ray showed clearance of
pulmonary infiltrates after 72 hours of ventilator support
and weaning was possible only after that (figure 2).
The initial differential diagnosis was between transfusion
mismatch, myocardial infarction, pulmonary embolism
and fluid overload. Absence of typical clinical features of
a cross-match reaction such as bronchospasm, rashes,
hemoglobinuria, renal shutdown, or falling hemoglobin
levels, along with a negative recheck for cross-match reac-
tion in the blood bank lab ruled out a mismatched trans-
fusion. Fluid overload was ruled out by a normal central
venous pressure (CVP) and normal echocardiogram
(ECHO). A normal electrocardiogram (ECG), normal
ECHO and near-normal cardiac enzymes ruled out the
possibility of an acute myocardial ischemic event. Pulmo-
nary embolism was excluded from the differential diagno-
sis on the basis of bilateral extensive pulmonary
infiltrates, normal D-dimer values and no clinical evi-
dence of deep vein thrombosis.
In this clinical setting, a possibility of TRALI was raised.
The patient's clinical features, course of events, and
response of the acute episode to supportive management,
were all supportive of this diagnosis.
The patient eventually recovered completely from this
acute pulmonary insult over the course of the next few
days and was discharged from hospital care by the 10th
postoperative day.
Discussion
TRALI is defined as non-cardiogenic pulmonary edema
temporally related to the transfusion of blood products
[1,2]. The current definition of TRALI (see below), by con-
sensus panel, includes two components, the first being
Acute Lung Injury (ALI), and the second being absence of
features of ALI before transfusion and its onset in tempo-
ral relation to transfusion of a blood product [2].
Chest X-ray findings (a) at the time of acute symptoms and (b) after weaning from the ventilator Figure 1
Chest X-ray findings (a) at the time of acute symptoms and (b) after weaning from the ventilator.Journal of Medical Case Reports 2008, 2:336 http://www.jmedicalcasereports.com/content/2/1/336
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Criteria for ALI (AECC guidelines 1994; Toy et al., 2005
[2])
1. Timing: acute onset
2. Pulmonary artery occlusion pressure ≤ 18 mmHg when
measured or lack of clinical evidence of left atrial hyper-
tension
3. Chest radiograph: Bilateral infiltrates seen on frontal
chest radiograph
4. Hypoxemia: Ratio of PaO2/FiO2 ≤ 300 mmHg regard-
less of the positive end-expiratory pressure level, or oxy-
gen saturation of ≤ 90% on room air.
In addition, for TRALI
1. Onset within 6 hours of transfusion of blood products
2. No pre-existing ALI before transfusion
3. TRALI still possible if another ALI risk is present
Flow chart to evaluate a case of acute lung injury within 6  hours of transfusion Figure 2
Flow chart to evaluate a case of acute lung injury 
within 6 hours of transfusion.
Table 1: Summary of immediate investigations done at the time of acute symptoms
S. No. Investigation Parameters Value Comments
1. ABG pH 7.447 Measured with O2 on flow at a rate of 10 liters/minute through nasal prongs
pCO2 23.8
pO2 30.7
SpO2 62.2
Hb 10.4
Hct 32
2. Invasive hemodynamic monitoring Arterial BP 85/48 Invasive monitoring instituted in view of the deteriorating hemodynamic 
status
CVP 12
3. ECG Normal sinus tachycardia (HR 144/minute) with no evidence of ischemic changes
4. ECHO Normal study with no evidence of RWMA, normal LA parameters, LVEF 55%
5. Chest X-ray Bilateral extensive pulmonary infiltrates, no effusion
6. Troponin T - 0.352 NR: 0–0.2 ng/ml
7. CK – MB - 47 NR: 0–23 IU/mlJournal of Medical Case Reports 2008, 2:336 http://www.jmedicalcasereports.com/content/2/1/336
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Massive transfusion should not exclude the possibility of
TRALI
In 1951, Barnard described the first case of fatal pulmo-
nary edema following transfusion therapy [3].
Popovsky is credited with having coined the term TRALI
in 1983 to refer to non-cardiogenic pulmonary edema
complicating transfusion therapy, when he reported a case
series of 36 patients over a period of 3 years [4].
With the reduction of clerical errors and with more effec-
tive screening and prevention of the transmission of infec-
tious agents, TRALI has surpassed hemolytic reactions as
the leading cause of transfusion-related mortality in devel-
oped countries. It is, thus, now emerging as one of the
most common serious complications of blood transfu-
sion [5]. The published incidence of TRALI ranges from
0.02% to 0.05% per blood product unit transfused and
from 0.08% to 0.16% per patient who received a transfu-
sion [6]. The true incidence of TRALI is not known
because there is significant under-reporting of cases [7].
Confusion surrounding TRALI is due to the numerous
eponyms that have been used in the past to refer to this
clinical entity. The syndrome had previously been referred
to as pulmonary hypersensitivity reaction, allergic pulmonary
edema, non-cardiogenic pulmonary edema and pulmonary leu-
koagglutinin reaction [7]. Consequently, the disease entity
is still under-recognized and under-reported for a multi-
tude of reasons, which vary from a lack of precise defini-
tion, misdiagnosis, to lack of awareness.
Almost any blood component containing about 50 ml or
more of plasma is implicated; use of red blood cells
(RBCs), and pooled platelets from several donors seems
to have a particularly high risk [5,6,8,9]. Rarely, cryopre-
cipitate, intravenous immunoglobulin, and stem cell
preparations have been implicated and it does not seem to
occur with washed red blood cells [10]. Interestingly, the
incidence is least with Fresh Frozen Plasma (FFP), and
maximal with platelet concentrates.
Symptoms of TRALI usually appear within 2 to 6 hours
from initiation of transfusion, but cases of presumed
TRALI have been described up to 48 hours after transfu-
sion [11]. Clinically, the patient presents with features of
acute onset respiratory and hemodynamic complications
in the absence of features of circulatory overload such as
dyspnea, tachypnea, frothy sputum, fever, hypotension,
or, much more rarely, hypertension [11].
The exact etiology of TRALI is unknown, but two distinct
mechanisms have been suggested. The traditional theory
proposes an antibody-mediated reaction between recipi-
ent granulocytes and anti-granulocyte antibodies from
donors who were sensitized during pregnancy (multipa-
rous women) or by previous transfusion [4,5].
Recently, an alternative mechanism has been suggested,
implicating pro-inflammatory molecules, predominantly
lipid products of cell degradation, known to accumulate
during storage of cellular blood products [12].
Both models are based on a two-hit hypothesis wherein a
first hit is required as an initial priming event followed by
a second initiator event. Of note, the two hypotheses of
TRALI pathogenesis are not mutually exclusive and may
even act synergistically with underlying patient factors to
produce acute lung injury.
The first insult (first hit) consists of priming and adher-
ence of neutrophils to the pulmonary endothelium. Can-
didate conditions for producing the first insult in TRALI
include surgery, sepsis, trauma, massive transfusions,
hematologic malignancies, cardiac surgeries, induction
chemotherapy and cardiopulmonary bypass [1].
The second insult (second hit) activates these primed neu-
trophils, resulting in the release of reactive oxygen species
that cause capillary leak and pulmonary edema [13]. For
the second hit, parity of the blood donor, relationship to
the blood donor, and the age of the blood products can all
be potential risk factors [1].
Although the antibody theory remains more widely
accepted and published, in some cases, there is definite
evidence of biologically active lipids in the etiogenesis of
TRALI.
The first step in the management of TRALI is to make a
correct diagnosis. This requires a high index of clinical
suspicion and awareness about this condition in the event
of any adverse episode temporally related to blood trans-
fusion to diagnose and treat this condition effectively. Fig-
ure 2 outlines the algorithm for diagnosis of a suspected
case of TRALI.
Differential diagnosis of TRALI includes, but is not limited
to, transfusion-related circulatory overload, anaphylac-
toid reaction to transfusate, bacterial contamination of
transfusate, and hemolytic transfusion reaction [8].
There are no specific investigations since there is no spe-
cific abnormality associated with TRALI. However, inves-
tigations are required to rule out other possibilities of a
transfusion-related reaction. Thus in regular clinical prac-
tice, TRALI is a diagnosis by exclusion because it has no
specific symptoms, signs or investigations. The only rou-Journal of Medical Case Reports 2008, 2:336 http://www.jmedicalcasereports.com/content/2/1/336
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tine laboratory parameter that has been associated, albeit
infrequently, with TRALI is leucopenia [8].
Laboratory findings for TRALI are inconsistent and
include acute transient neutropenia, presence of matching
leukocyte antigen-antibody in the donor and recipient,
and increased neutrophil priming activity in transfused
blood [6,8].
Clinically useful tests to differentiate between cardiogenic
pulmonary edema and TRALI include B-type natriuretic
peptide (BNP) and determination of the protein concen-
tration in the pulmonary edema fluid and serum.
In patients with an endotracheal tube in place, high pro-
tein concentration found in edema fluid sampled within
the first hour of intubation may help differentiate TRALI
from fluid overload and cardiogenic pulmonary edema
[1]. Edema fluid/plasma protein ratio measured by taking
matched samples of edema fluid from an endotracheal
tube and plasma sample for protein measurements can be
diagnostic of increased permeability pulmonary edema.
In hydrostatic pulmonary edema, this ratio is <0.65, while
it is >0.75 with increased permeability pulmonary edema
[2]. This method is valid only for undiluted pulmonary
edema fluid, not BAL.
BNP is a biochemical marker of volume and pressure
overload [14]. It is secreted from the ventricles in response
to changes in pressure when heart failure develops. TRALI
is more likely if the BNP is less than 150 pg/ml; however,
BNP of more than 250 pg/ml is indicative of congestive
heart failure.
A scheme of proposed investigations in a case of any
adverse clinical event temporally associated with blood or
blood product transfusion is given in Table 2. In the
majority, TRALI is a self-limiting condition that is
believed to have a better short-term prognosis than other
causes of acute lung injury [1].
Management of TRALI is supportive, as it is for any patient
with permeability pulmonary edema, and often includes
ventilatory support. Most patients recover with supportive
care although approximately two-thirds of patients will
require mechanical ventilation with a hospital mortality
of 5 to 15% [8].
Patients with TRALI are often normotensive to hypoten-
sive with normal or low filling pressures [1]. Too often,
hypoxia that develops after transfusion therapy is ascribed
to volume overload, and diuretics are empirically admin-
istered. Mild to moderate cases of TRALI may be misdiag-
nosed as volume overload, and the chance to make a
Table 2: Proposed scheme of investigations for an adverse event following a transfusion
S. No. Investigation Comment
1. ABO typing To confirm type
2. Direct anti-globulin test To exclude cross-match incompatibility
3. Complete blood counts Transient neutropenia is seen with TRALI
4. Peripheral blood film Hemolytic cells may be seen in cross-match reaction
5. Chest X-ray Needed to exclude pulmonary edema, pneumonia, other reasons for hypoxia
6. Blood cultures Bacterial contamination is a differential diagnosis
7. Anti-body panel Includes anti HLA-1 & HLA-2, anti granulocyte, anti monocyte, anti IgA
8. D-dimer/FDP To evaluate for deep vein thrombosis
9. ECHO For cardiac function status and fluid overload
10. ECG/Cardiac enzymes For cardiac function status (to exclude myocardial infarction)
11. Undiluted pulmonary edema fluid From endotracheal tube if present – can be diagnostic if fluid to serum protein ratio is >0.75
12. BNP Helps to rule out overload in difficult cases (TRALI more likely if BNP < 150 pg/ml)
FDP: fibrin degradation products; ECHO: echocardiogram; BNP: B type natriuretic peptideJournal of Medical Case Reports 2008, 2:336 http://www.jmedicalcasereports.com/content/2/1/336
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diagnosis of TRALI, and possibly prevent future cases, is
lost. There is evidence that diuretics may be contraindi-
cated, and intravenous fluids should be administered as
necessary, titrated to achieve mean arterial pressures of 60
mmHg with appropriate urine output [14]. Invasive
hemodynamic monitoring may be necessary in especially
severe cases to guide fluid management [1,15]. For mild
TRALI cases, supplemental oxygen and supportive care
may be sufficient for treatment. For the more severe cases,
intravenous fluids and mechanical ventilation are neces-
sary. Lung protective (low tidal volume with low plateau
pressures) ventilatory strategies should be employed
when ventilating TRALI patients [15].
There are reports, but no prospective randomized trials, of
use of glucocorticoids in the management of TRALI and,
at present, their role in this setting remains unsettled [11].
Recurrent TRALI cases have been described [16], so indi-
cations for future transfusions in a TRALI patient should
be scrutinized and the patient monitored carefully to
determine if a transfusion is needed at all.
Conclusion
TRALI is emerging as one of the most common causes of
self-limiting, yet potentially life-threatening, transfusion
associated morbidity, and diagnosis requires a high
degree of suspicion. It is based primarily on exclusion of
other causes and the supportive clinical picture in the set-
ting of a temporal relation to blood product transfusates.
Correct diagnosis is important as diuretics are contraindi-
cated and hypovolemia needs to be corrected. Treatment
is mainly supportive, with a significantly better prognosis
compared to other causes of acute lung injury.
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